Tecentriq (Atezolizumab) Receives FDA Supplemental Approval for Efficacy

The U.S. Food and Drug Administration (FDA) granted a supplemental application approval for Tecentriq (atezolizumab) on June 14, 2018. This approval, identified as BLA 761034 S-8, was based on new efficacy data submitted by the sponsor, Genentech Inc.

Background

Atezolizumab, marketed as Tecentriq, is a therapeutic agent developed by Genentech Inc. Supplemental applications to the FDA are typically submitted to request approval for changes to an already approved drug. These changes can include new indications, new dosing regimens, new manufacturing processes, or updates to the drug's label. In this instance, the supplemental application specifically pertained to new efficacy data, suggesting that the drug demonstrated clinical benefit in an additional context or patient population not covered by its previous approvals. Such approvals are critical for expanding the utility and accessibility of established treatments to a wider range of patients who may benefit from them.

What this means

This supplemental approval for Tecentriq (atezolizumab) indicates that the FDA has thoroughly reviewed and accepted new clinical data demonstrating the drug's efficacy for an expanded or updated use. While the specific details of the new indication or patient population are not provided in the available data, this type of approval signifies a positive regulatory milestone. It allows Tecentriq to be prescribed for a broader range of conditions or patient groups, thereby increasing its clinical applicability. For clinicians, this means an expanded set of treatment options for their patients, supported by new evidence of efficacy. For patients, it potentially opens access to an effective treatment for conditions where it may not have been previously approved. This decision reflects the ongoing process of evaluating and refining the therapeutic landscape for approved medications.

Source

The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for Tecentriq (atezolizumab), identified as BLA 761034 S-8, was granted on June 14, 2018, and is publicly accessible on accessdata.fda.gov. The source document specifies the event as a supplemental application approval for efficacy, with Genentech Inc. as the sponsor.